Endeavor resolute trial

Four-month angiographic and clinical results reinforce that zotarolimus continues to be a very potent drug in preventing restenosis, even in challenging patient populations. Current drug-eluting stents DES do not meet all the requirements of physicians who deal with the most challenging clinical cases, such as patients with diabetes.

This new polymer is designed to help match the duration of drug delivery with the longer healing duration often experienced by patients with complex medical conditions. BioLinx is different than other polymers in that its outer surface is hydrophilic water friendly , which leads to high biocompatibility with the body, while the interior of the polymer is hydrophobic, which helps to precisely control the drug release. In 30 patients with four-month angiographic follow-up, in-stent late loss was 0.

Both in-stent and in-segment binary restenosis were zero, and intravascular ultrasound IVUS results showed neointimal volume obstruction of 2. Patients seen in routine clinical practice are eligible for enrollment -- the meaning of "All-Comers. One of the trial's primary endpoints is TLF at 12 months post-procedure. All patients will be followed for five years. The primary endpoint is a composite of cardiac death and myocardial infarction not clearly attributable to a nontarget vessel at one year post-procedure.

Ian Meredith of Monash Medical Centre in Melbourne, Australia, characterized as presenting "with especially complex and challenging characteristics. Patients treated with the Endeavor Resolute stent in RESOLUTE required no repeat procedures through nine months post-procedure and had experienced no protocol-defined stent thrombosis through 12 months of follow-up.

In-stent late lumen loss at nine months, the study's primary endpoint, was met at 0. Among the trial's patients, only one required clinically-driven TLR or target vessel revascularization TVR through 12 months post-procedure.

At the same timepoint, the incidence of major adverse cardiac events MACE was 8. Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.

Catheter Cardiovasc Interv. Epub Nov 1. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome. Epub Mar Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

J Am Coll Cardiol. Epub Apr Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial. Epub Mar 8. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

Epub Feb TWENTE randomized study stent coronary stent drug-eluting stent Zotarolimus Everolimus Xience V Endeavor Resolute head to head comparison real world patients target vessel failure investigator initiated study coronary artery disease coronary arteries atherosclerosis non inferiority. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Phase 4. Study Type :.

Interventional Clinical Trial.